OncoCyte Corp
NASDAQ:OCX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.44
4.26
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OCX stock under the Base Case scenario is 3.58 USD. Compared to the current market price of 2.72 USD, OncoCyte Corp is Undervalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
OncoCyte Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OCX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
OncoCyte Corp
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
OncoCyte Corp
Balance Sheet Decomposition
OncoCyte Corp
Current Assets | 4.8m |
Cash & Short-Term Investments | 3.4m |
Receivables | 209k |
Other Current Assets | 1.2m |
Non-Current Assets | 65.4m |
PP&E | 6.5m |
Intangibles | 56.5m |
Other Non-Current Assets | 2.4m |
Current Liabilities | 9.1m |
Accounts Payable | 872k |
Accrued Liabilities | 7.9m |
Other Current Liabilities | 364k |
Non-Current Liabilities | 51.4m |
Long-Term Debt | 653k |
Other Non-Current Liabilities | 50.8m |
Earnings Waterfall
OncoCyte Corp
Revenue
|
709k
USD
|
Cost of Revenue
|
-824k
USD
|
Gross Profit
|
-115k
USD
|
Operating Expenses
|
-43.5m
USD
|
Operating Income
|
-43.6m
USD
|
Other Expenses
|
-17k
USD
|
Net Income
|
-43.6m
USD
|
Free Cash Flow Analysis
OncoCyte Corp
USD | |
Free Cash Flow | USD |
OCX Profitability Score
Profitability Due Diligence
OncoCyte Corp's profitability score is 8/100. The higher the profitability score, the more profitable the company is.
Score
OncoCyte Corp's profitability score is 8/100. The higher the profitability score, the more profitable the company is.
OCX Solvency Score
Solvency Due Diligence
OncoCyte Corp's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
OncoCyte Corp's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCX Price Targets Summary
OncoCyte Corp
According to Wall Street analysts, the average 1-year price target for OCX is 4.21 USD with a low forecast of 4.04 USD and a high forecast of 4.46 USD.
Dividends
Current shareholder yield for OCX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
OCX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.
Officers
The intrinsic value of one OCX stock under the Base Case scenario is 3.58 USD.
Compared to the current market price of 2.72 USD, OncoCyte Corp is Undervalued by 24%.